Session » Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1840

A Dichotomy of Regulatory Immunome Is Related to Disease Activity in Juvenile Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1831

A Novel Graph Theoretic Approach Applied to Modular Repertoire Analysis Identifies a Dual Molecular Progression in Adult SLE Patients, with Distinct Interferon and Neutrophil Transcription Patterns

9:00AM-11:00AM: Abstract Number: 1823

African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in CD4+ T Cell and Monocyte Pathways

9:00AM-11:00AM: Abstract Number: 1838

Antibodies Against Bacterial Products Curli/DNA Are Found in Lupus Patients and Are Associated with Disease Flares

9:00AM-11:00AM: Abstract Number: 1833

Autoantibody Response to TROVE2 in Systemic LUPUS Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1822

CD4+ T Cell Lymphopenia Is Associated with Deficient Ubiquitination of the Cell Cycle Inhibibitor p27kip1 By the E3 Ligase Casitas B-Lineage Lymphoma-b in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1834

Commensal Ro60 Autoantigen Ortholog Cross-Reactivity in Human Lupus and Gnotobiotic Models

9:00AM-11:00AM: Abstract Number: 1820

Dectin-1 on Monocytic Cells Mediates Aberrant Innate and Adaptive Immune Responses in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1821

Demethylated CD4+CD28+KIR+CD11ahi T Cells Are Characterized By a Pro-Inflammatory Transcriptome and Interact with Genetic Risk to Predict Disease Activity in Lupus

9:00AM-11:00AM: Abstract Number: 1841

Dysregulation of the Splicing Machinery Components in Leukocytes from Patients with Systemic Lupus Erythematosus: Influence on Autoimmune and Atherothrombotic Mechanisms

9:00AM-11:00AM: Abstract Number: 1839

Elevated Plasma Cell-Free Mitochondrial DNA Defines a Subgroup of Lupus Patients with Membranous Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1837

Genetic Susceptibility Loci for Systemic Lupus Erythematosus in the Dominican Republic Population

9:00AM-11:00AM: Abstract Number: 1829

Hyper-Responsiveness to TLR-4 Stimulation in SLE: Association with High Levels of Serum IFN-Alpha and a Distinct Inflammatory Cytokine Profile

9:00AM-11:00AM: Abstract Number: 1832

Increased Interferon b Expression in Bone Marrow Mediates a Senescent Phenotype and Impaired Production of Immunomodulatory Factors By SLE Mesenchymal Stromal Cells

9:00AM-11:00AM: Abstract Number: 1844

Mesenchymal Stem Cells Ameliorate the Deficiencies in Immunomodulatory and Phagocytic Capacities of Lupus Macrophages

9:00AM-11:00AM: Abstract Number: 1828

Metabolic Reprogramming in CD4+CD28-CXCR3intt-bethi cells and Its Relevance to Pathogenesis in Patients with SLE

9:00AM-11:00AM: Abstract Number: 1824

Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients

9:00AM-11:00AM: Abstract Number: 1842

Pentraxin 3 Level Positively Correlated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1843

Single Cell Expression Quantitative Trait Loci (eQTL) Analysis of Established SLE-Risk Loci in Lupus Patient Monocytes

9:00AM-11:00AM: Abstract Number: 1836

SLE Bone Marrow Contains Factors That Promote Type I Interferon Activation

9:00AM-11:00AM: Abstract Number: 1826

STAT3 Phosphorylation Mediates the Stimulatory Effects of Interferon Alpha on B Cell Differentiation and Activation in SLE

9:00AM-11:00AM: Abstract Number: 1835

Study on the Expression of NOD2 in Lupus Nephritis and Its Potential Signaling Pathway

9:00AM-11:00AM: Abstract Number: 1825

the Non-Coding Genome and the Genetics of Systemic Lupus

9:00AM-11:00AM: Abstract Number: 1830

The Role of Tripartite Motif-Containing 21 in Interferon Signature of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1827

Type I IFN Signature Low and High SLE Subjects with Moderate to Severe Disease Activity Have Distinct Gene Expression Signatures of Immunologic Pathways and Cell Types

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].